163.40
+2.96%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ipsen
Its shares trade on Euronext Paris under the ticker IPN.PA. It has been listed since 6 December 2005. In the fiscal year to 31 December 2025, it reported revenue of €3.68bn and net income of €444.5m. At that date it held total assets of €6.94bn and shareholders' equity of €4.34bn.
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Dec 2005
- Employees
- 5,807
- Website
- ipsen.com ↗
Leadership
Pay as last reported
- Mr. Marc De GaridelChairman of the Board, since 2010€600,000
- Mr. David LoewChief Executive Officer, Director, since 2020€2.2m
- Mr. Antoine FlochelVice Chairman of the Board€165,000
- Mr. Aymeric Le ChatelierChief Financial Officer, Executive Vice President
- Mr. Regis MulotChief Human Resources Officer, Executive Vice President
- Mr. Francois GarnierExecutive Vice President, General Counsel, Chief Business Ethics Officer
- Ms. Caroline SitbonExecutive Vice President, General Counsel
- Mr. Bartosz BednarzExecutive Vice President, Head of Global Product and Portfolio Strategy
- Ms. Olivia BrownExecutive Vice President, Global Head - Neurotoxins
- Mr. Josep CatllaExecutive Vice President, Chief Corporate Affairs Officer
- Ms. Keira DrianskyExecutive Vice President, President of North America
- Mr. Andreas GerberExecutive Vice President, Head of International
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 99
- Social
- 99
- Governance
- 41
- Direct emissions (scope 1)
- 11,516 t
- Energy emissions (scope 2)
- 6,588 t
- Value chain emissions (scope 3)
- 21,249 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- One of Ipsen SA's key strengths is its diversified pharmaceutical product portfolio, which includes innovative therapeutics across multiple therapeutic areas. This diversification reduces the company's reliance on a single product or therapeutic area, providing a more stable revenue stream.
- Another strength of Ipsen SA is its strong global presence. The company operates in over 115 countries worldwide, enabling it to tap into various markets and reach a wide range of patients. This global reach allows Ipsen to leverage opportunities in different regions and mitigate risks associated with specific markets.
Weaknesses
- One weakness of Ipsen SA is its dependence on a few key products for a significant portion of its revenue. The loss of exclusivity or patent expiration of these products could have a substantial negative impact on the company's financial performance.
- Another weakness is Ipsen's limited presence in certain geographic regions. Although the company has a strong global reach, it may face challenges in penetrating or expanding its market share in certain countries, limiting its growth potential.
Opportunities
- One major opportunity for Ipsen SA lies in the growing demand for targeted therapies and precision medicine. As technological advancements continue to transform the healthcare industry, Ipsen can capitalize on this trend by developing and commercializing innovative products that cater to specific patient populations.
- Furthermore, Ipsen can explore strategic partnerships and collaborations with other pharmaceutical companies or research institutions to enhance its pipeline and expand into new therapeutic areas.
Threats
- One significant threat faced by Ipsen SA is the increasing competition in the pharmaceutical industry. The presence of well-established pharmaceutical companies, generic manufacturers, and emerging biotech firms can potentially challenge Ipsen's market share and profitability.
- Moreover, changing regulatory landscapes and pricing pressures in different regions can pose threats to Ipsen's operations and financial performance. Adapting to evolving regulations and managing pricing pressures are essential for the company to maintain its competitiveness.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.